Relmada Therapeutics (RLMD) CFO reports stock buy and 828,000 SAR grant

Rhea-AI Filing Summary

Relmada Therapeutics, Inc.'s chief financial officer reported buying 11,665 shares of common stock on December 15, 2025 at $4.12 per share, bringing his directly held stake to 800,000 shares. In a separate transaction on December 12, 2025, he was granted 828,000 stock appreciation rights with a $4.06 exercise price, each linked to one share of common stock and expiring on December 12, 2035. These rights begin vesting on March 12, 2026 in 16 equal quarterly installments, providing additional long-term equity-based compensation tied to the company’s stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shenouda Maged

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		P		11,665	A	$4.12	800,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$4.06	12/12/2025		A		828,000		03/12/2026(1)	12/12/2035	Common Stock	828,000	$0	828,000	D

Explanation of Responses:

1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

	/s/ Maged Shenouda	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Relmada Therapeutics (RLMD) report for its CFO?

The filing shows the chief financial officer acquired 11,665 shares of Relmada Therapeutics common stock on December 15, 2025 and received a grant of 828,000 stock appreciation rights on December 12, 2025.

How many Relmada Therapeutics (RLMD) shares did the CFO buy and at what price?

The chief financial officer purchased 11,665 shares of Relmada Therapeutics common stock at a price of $4.12 per share on December 15, 2025.

How many Relmada Therapeutics (RLMD) shares does the CFO own after the reported transaction?

After the reported purchase, the chief financial officer beneficially owns 800,000 shares of Relmada Therapeutics common stock in direct ownership.

What stock appreciation rights were granted to the Relmada Therapeutics (RLMD) CFO?

The chief financial officer was granted 828,000 stock appreciation rights on December 12, 2025, with a $4.06 exercise price and each right tied to one share of Relmada Therapeutics common stock.

When do the Relmada Therapeutics (RLMD) CFO’s stock appreciation rights vest and expire?

The stock appreciation rights start vesting in 16 equal quarterly installments beginning on March 12, 2026 and have an expiration date of December 12, 2035.

What is the ownership form of the Relmada Therapeutics (RLMD) CFO’s reported holdings?

The filing indicates that both the 800,000 shares of common stock and the 828,000 stock appreciation rights are held in direct ownership by the chief financial officer.